A four-year longitudinal study of bone loss in patients with inflammatory bowel disease

Motley, Richard; Clements, D.; Evans, W. D.; Crawley, E.O.; Evans, Carol; Rhodes, J.; Compston, Juliet

doi:10.1016/s0169-6009(08)80046-3

Cited by 84 publications

(30 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although glucocorticoid treatment is one of the postulated pathogenic factors for osteoporosis in IBD [1,3,31,32], current use of glucocorticoid was not associated with decreased BMD in the present study. Unfortunately, the possible involvement of glucocorticoid could not be Values represent the mean±SD, and comparison between CD and UC groups was made with unpaired t test **p<0.01, statistically significant difference from zero with onesample t test in the Z score evaluated in more detail, since most of them were referred to the university hospital from another hospital and cumulative dose of glucocorticoid could not be precisely calculated.…”

Section: Discussioncontrasting

confidence: 66%

High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 66%

High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease

et al. 2008

View full text Add to dashboard Cite

show abstract

“…These findings suggest that CD itself plays an important role in the development of osteopenia/osteoporosis, and that a low BMD cannot be attributed solely to treatment with steroids. Corticosteroids have been shown to reduce the BMD [2,9,10,11,12,13,14,15,16], although the data are conflicting [5, 6,17,18,19,20,21]. …”

Section: Introductionmentioning

confidence: 99%

Analysis of Risk Factors for Low Bone Mineral Density in Inflammatory Bowel Disease

et al. 2006

View full text Add to dashboard Cite

Background/Aim: Several risk factors have been suggested for osteoporosis which frequently occurs in inflammatory bowel disease (IBD) patients. We studied prevalence and risk factors for reduced bone mineral density (BMD) in IBD patients at the University Hospital of Zürich, Switzerland. Methods: The BMD was determined by dual-energy X-ray absorptiometry at the lumbar spine and femoral neck in 88 IBD patients (55 with Crohn’s disease, 30 with ulcerative colitis, and 3 with indeterminate colitis). Z scores were obtained by comparison with age- and sex-matched normal values, and T scores by comparison with sex-matched healthy young adults. Osteopenia and osteoporosis were defined according to the WHO guidelines. Predictive factors for BMD were analyzed by group comparison and stepwise regression analysis. Results: Osteopenia was present in 43% of the patients at the lumbar spine and in 42% of them at the femoral neck. Osteoporosis was present in 14% of the patients at the lumbar spine and in 5% of them at the femoral neck. At the lumbar spine, stepwise regression analysis showed that body mass index, age, number of bowel resections, topic steroids, and azathioprine correlated with the Z scores. Cumulative steroid dose, topic steroids, age and bowel resection were found to be predictors for a pathological T score. At the femoral neck, regression analysis showed that body mass index, age, topic steroids, and azathioprine correlated with the Z scores. Only a low body mass index was a significant predictor for pathological femoral T scores. Conclusions: Osteopenia and osteoporosis are commonly found in IBD patients. Steroid treatment and bowel resection were significant risk factors for osteoporosis of the lumbar spine. However, disease-inherent factors also appear to confer a major risk, indicating that the BMD should be determined in all IBD patients, irrespective of steroid treatment.

show abstract

“…26 X-ray images of the spine most commonly show wedge or compression deformities. A variety of studies have demonstrated both decreased bone mineral density (BMD) in patients with IBD, and increased rates of bone loss when followed longitudinally 27,28 in comparison to healthy controls. The current Gold standard for measuring bone mass is dual-energy X-ray absorptiometry (DEXA).…”

Section: Discussionmentioning

confidence: 99%

Bone loss in inflammatory Bowel disease: our multicentric study

Geraci¹,

Tomasello²,

Damiani³

et al. 2011

Endocrinol Studies

View full text Add to dashboard Cite

Patients with inflammatory bowel disease are at increased risk of developing disorder in bone and mineral metabolism The study was aimed to determine if inflammatory bowel disease (IBD) is a risk factor for osteoporosis in 103 adult patients. We included 103 IBD patients, 67 patients with Crohn's disease (CD) and 36 with ulcerative colitis (UC). Bone mineral density was measured by dual-energy X-ray absorptiometry. We used T score to express bone loss (osteopenia: -2.5 SD 2 years) and active disease would be risk factors of bone mineral loss in IBD.

show abstract

A four-year longitudinal study of bone loss in patients with inflammatory bowel disease

Cited by 84 publications

References 27 publications

High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease

High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease

Analysis of Risk Factors for Low Bone Mineral Density in Inflammatory Bowel Disease

Bone loss in inflammatory Bowel disease: our multicentric study

Contact Info

Product

Resources

About